Drugs / D5W
D5W
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07568470 | Apr → Sep 2026 overdue | — | US Neuropathy Centers | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00460499 Comparator | Jul 2004 → Mar 2015 | glucose metabolism disease | American Heart Association | Completed | No outcome recorded |
| Phase 3 | NCT06030609 Comparator | Sep 2024 → Feb 2026 | disorder of acid-base balance | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D5W | “These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl” NCT00460499 ↗2“Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ |
| Known as | 5% Dextrose in Water | “non-guided subcutaneous infiltration of D5W (5% Dextrose in Water)” NCT07568470 ↗ |
| Known as | dextrose water | “Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ |
| Route | Intravenous | “D5W+80unitsInsulin+40mEqKCL IV” NCT00460499 ↗ |